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Background: The South African Expanded Programme on
Immunisation (EPI-SA) currently vaccinates against 10 childhood
vaccine preventable diseases. Six injections are required for pri-
mary vaccination against diphtheria, tetanus, pertussis, polio,
Haemophilus inﬂuenza type b and hepatitis B: three DTaP-IPV//Hib
[Pentaxim®] doses and three monovalent Hep B vaccines to chil-
dren under 12 months of age, with a seventh injection (Pentaxim®
booster) at 18 months. Madhi et al (PIDJ 30:e68 2011) demon-
strated no signiﬁcant difference in the safety and efﬁcacy between
Pentaxim® plus monovalent Hep B and a new fully liquid hexa-
valent vaccine, Hexaxim® (DTaP-IPV-Hib-HepB). Fromahealthcare
provider perspective, combination vaccines could reduce costs,
simplify logistics anddelivery infrastructure, and improvecoverage
with fewer injections. This study aimed to analyse the cost implica-
tions of a switch from the current combination of Pentaxim® plus
monovalent Hep B injections, to a single Hexaxim® injection, from
the public sector perspective.
Methods & Materials: Data were collected to derive direct
costs, i.e. vaccines’ prices (except Hexaxim®, no price yet avail-
able), transportation charges, cold chain storage, vaccine wastage
rate, hazardouswastedisposal andvaccineadministration.All costs
were calculated per dose, and expressed in South African Rand (R)
(USD 1.00=R10.19 per 2013 exchange rate). Indirect costs such as
individual and societal beneﬁts were excluded.
Results: Delivering one dose ofPentaxim® and Hep B costs
R166.30. Reduced volumes result in cost reductions when using
Hexaxim® for: cold storage; hazardous waste disposal; and vac-
cine administration, resulting in an estimated saving of R10.52 to
R29.40 per dose, depending on utilisation of usable cold storage
space.
Conclusion: Implementation of Hexaxim® within EPI-SA is
highly recommended, because it reduces healthcare provider costs
by simplifying logistics and delivery infrastructure. From a com-
munity perspective, such vaccines reduce clinic visits, vaccinators’
errors, number of injections and side effects,which translate to bet-
ter acceptability, convenience and increased compliance. As theuse
of Hexaxim® demonstrates direct and indirect cost savings, poten-
tial public sector introduction should be valued not only in terms
of the price of Pentaxim® and Hep B.
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Background: Pregnant women are at increased susceptibility
to severe inﬂuenza-illness and are recommended by WHO to be a
priority group for inﬂuenza vaccination. The aims of our studywere
to assess the immunogenicity of trivalent IIV (IIV3) in pregnant
women vaccinated during their 2nd/3rd trimester and to calculate
the vaccine efﬁcacy (VE) to PCR-conﬁrmed inﬂuenza illness (PCI).
Methods & Materials: A double-blind, randomized, placebo-
controlled trial was undertaken in Soweto, South Africa in 2011
and 2012. 2116 conﬁrmed HIV-uninfected pregnant women were
randomized to receive either IIV3 or normal saline placebo
intramuscularly. Immune responses to each vaccine-strain, using
hemagglutination-inhibition (HAI) assays were measured pre-
vaccination and one month post-vaccination. HAI titres of ≥1:40
were categorizedas seroprotective andseroconversionwasdeﬁned
as at least a 4-fold increase in titres from pre- to post-vaccination.
Participants were followed until six months post-partum for the
presence of acute respiratory illness or hospitalization for acute
cardio-pulmonary illness. When ILI was conﬁrmed by a study
physicianoropharyngeal andnasopharyngeal swabswerecollected
for inﬂuenza virus testing by real-time PCR.
Results: One month post-vaccination, comparing IIV3 and
placebo-recipients, the proportion of women who seroconverted
were 72.5% vs. 8.1% to A/H1N1pdm09, 64.8% vs. 2.7% to H3N2,
92.3% vs. 2.0% to inﬂuenza-B strain (all comparisons p<0.001).
Post-vaccination, theproportionofwomenwith seroprotectiveHAI
titres were 93.7% vs. 48.0% for A/H1N1pdm09, 78.9% vs. 27.0% for
H3N2 and 97.2% vs. 29.1% for inﬂuenza-B (p<0.001 for all com-
parisons). The vaccine efﬁcacy of IIV3 was 46.1% (95%CI: 6.4% to
69.0%) in protecting against PCI due to homotypic vaccine strains
and 50.4% (95%CI: 14.5 to 71.2) when including the 3 non-vaccine
inﬂuenza B-Yamagata cases that exclusively occurred among the
placebo-recipients. The dominant strain of inﬂuenza virus identi-
ﬁed was H3N2 which composed 22 (57.9%) cases in the placebo
group and 10 (52.6%) in the vaccinees. 174 and 181 IIV-recipients
and placebo-recipients, respectively, had at least one ILI medical
visit. IIV3 was not associated with reduction of ﬁrst episode of ILI
(VE: 4.6%; 95%CI: -15.4% to 21.1%).
